Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated July 15, 2022 Relating to the Preliminary Prospectus dated July 13, 2022 Registration Statement File No. 333-265860



Revolutionizing CAR-T Therapy

JULY 2022

NASDAQ: KRBP Kiromic.com

Forward Looking Statements

This presentation contains forward-looking statements that involve substantial risks and uncertainties. Kiromic makes looking statements pursuant to the safe harbor provisions of the United States Private Securities Litigation Reform Act, the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements other than statemer facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as: "wi "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," or the negative of other comparable terminology. These forward-looking statements include, but are not limited to, statements regar current and anticipated IND applications including statements regarding the scope of and timing for submission of an II the Deltacel[™] product platform; the sponsored research agreement and the data that will be generated as a result of such the timing for submitting and activating Kiromic's IND applications; the benefits of utilizing non-genetically engineered (cells as our first in-human study; Kiromic's ability to achieve its objectives; and the timing for the initiation and successful Kiromic's clinical trials of its product candidates. These forward-looking statements involve known and unknown risks, un other factors that may cause actual results, levels of activity, performance, or achievements to be materially diffe information expressed or implied expressed or implied by these forward-looking statements. These risks and uncertainti are not limited to, the risks and uncertainties discussed in our Annual Report on Form 10-K for the year ended December as detailed from time to time in our SEC filings. You should not rely upon forward-looking statements as predictions of Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guar future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements w or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the fe statements. Such forward-looking statements relate only to events as of the date of this press release. We undertake n update any forward-looking statements except to the extent required by law.

Free Writing Prospectus

This presentation highlights basic information about us and the proposed offering. Because it is a summary, it does not cc information that you should consider before investing.

We have filed a registration statement (including a preliminary prospectus) with the SEC for the offering to which the relates, which registration statement has not yet been declared effective by the SEC (File No. 333-265860). Before you inverse the preliminary prospectus and the registration statement (including the risk factors described therein) for n information about us and the offering.

You may access these documents for free by visiting EDGAR on the SEC Website at http://www.sec.gov. Alternative underwriter participating in the offering will arrange to send you the prospectus if you contact ThinkEquity LLC, Prospectu 17 State Street, 41st Floor, New York, New York 10004, telephone: (877) 436-3673 or e-mail: prospectus@think-equity.com

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of the any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qual the securities laws of such state or jurisdiction. The offering is only being made by means of the prospectus.

Offering Summary

Issuer	Kiromic BioPharma, Inc.				
Symbols	Nasdaq: KRBP, KRBPW				
Expected Offering Size	Approximately \$25,000,000 + 15% Over-allotment Option				
Securities Offered	One common share and one 5-year warrant (or for purchasers who cannot beneficially own more than 4.99% of the outstanding shares of com- funded warrant and one warrant)				
Use of Proceeds	 Submission and the clinical trial activation of IND #1, which is our Deltacel[™] product candidate in standard anti-tumor modality. IND resubmission of the IND for ALEXIS-PRO-1 and the corresponding trial activation. Intellectual property protection and reinforcement. IND applications and IND enabling trials for our other product candidates. Research and development, and potential acquisitions/investments. Working capital; personnel expenses, general corporate purposes, including but not limited to legwith pending matters. We may also be required to apply a portion of the net proceeds for: Litigation expenses and to pay in connection with a judgment or settlement of private and against us, including the payment of any government fines or penalties. 				
Sole Book-Runner	ThinkEquity				




The Kiromic Difference

Kiromic BioPharma is the only cell therapy company combining Al-driven genetically edited Gamma Delta T-cells (GDT) with proprietary targeting technology to address solid malignancies.




Strategic Competitive Landscape

6 Known Companies (including Kiromic) in the Gamma Delta T Cell Therapy space. No Known Competitors with Al-driven Technology Combined with a Gamma Delta CAR-T Delivery Platform.



Solid Malignancy Market Opportunity



Competitive Difference


Allogeneic Gamma Delta Based T Cell Therapies






Artificial Intelligence and Bioinformatic Analytic Discovery & Development Platform

Algorithms and Large-Scale Genomics Analysis for Target Prediction




The Kiromic Difference - Diamond AI[™] Target Discovery Platform

Diamond AI[™] target discovery platform powers innovation and significantly reduces development time and cost.






Kiromic GDT Cell Therapy (Deltacel[™], Procel[™], and Isocel[™]) Multiple Potential Indications




Gamma Delta T-Cells (GDT): Guardians of the Immune System



Deltacel[™]: Non-Viral Gamma Delta T-Cell Development



GDT Cell Therapy Mechanism of Action: Targeting Unique Identifiers on Tumor Tissues




GDT chPD1 T Cell Therapy (Procel[™])* **Strong Efficacy**

Procel[™] eradicates established NCI-H226 pleural epithelioid mesothelioma

○ Saline Cont ▲ GDT ● chPD1-GDT (mm³ Tumor Tumor Volume eradication 11 12 13 14 15 5 **Days Post T Cell Administration** 100 % Tumor-bearing Animals O Saline ★ GDT ♦ chPD1-GDT 80 Overall 60 Survival ####P < 0.0001 40 20 0+ 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 **Days Post T Cell Administration**

GDT chPD1 T Cell Therapy (Proc **Strong Safety**

Procel[™] does not lead to cytokine level increases modeled or CRS, with circulating cell numbers regulated by objective



and extends survival.


*Preclinical models: nude mice with subcutaneous NCI-H226 cells injections


GDT CAR-T Cell Therapy (Isocel[™])* Strong Efficacy

GDT CAR-T Cell Therapy (Isocel^{TI} Strong Safety



Isocel[™] does not lead to cytokine level increases modeled to CRS, with circulating cell numbers regulated by objective







Pipeline


Clinical Trial Candidate	MD Anderson Principal Investigat	Target	Pre-Clinical
New IND #1 DeltaceI TM In combination with standard antitumor modality Allogeneic, Non-Viral, Non-engineered off-the-shelf GDT therapy	SRA Yes	Universal Non-Engineered	Q4 Exper Proce Trial
New IND #2 Procel [™] in combination with standard antitumor modality Allogeneic, off-the-shelf, GDT CAR-T therapy	Yes	PD-L1	Q2 Expec Proce Trial
ALEXIS - PRO-1 ProceI TM Allogeneic, off-the-shelf, GDT CAR-T therapy	No	PD-L1	Q2 Expec Proce Trial
New IND #3 Isocel [™] in combination with standard antitumor modality Allogeneic, off-the-shelf, GDT CAR-T therapy	Yes	lsoform of Mesothelin	Q4 Targe Proce Trial
ALEXIS - ISO-1 IsoceI TM Allogeneic, off-the-shelf, GDT CAR-T therapy	No	Isoform of Mesothelin	Q4 Targe Proce Trial

Use of Proceeds



In-House Manufacturing Creates De-Risked Value





Kiromic's Next 12 Months Upcoming Milestones*



ACHIEVED MILESTONE WITH TIMELY COMPLETION OF EXPANDED CGMP MANUFACTURING F, SUPPORT CELL THERAPY ONCOLOGY PIPELINE ✓ End of Q2 2022



Submission of New IND #1 (Deltacel in combination with standard antitumor modal
H2 2022

3

Expected Beginning of Activation Process for New IND #1 Clinical Trial

• End of Q4 2022



Submission of Amended IND for ALEXIS-PRO-1 and New IND #2 (Procel in combinati standard antitumor modality)

• H1 2023



Expected Beginning of Activation Process for ALEXIS-PRO-1 and New IND #2 Clinical
End of Q2 2023

*The milestones and timing of completion are based upon the company's current expectations in consultation with its partners and vendors.

Leadership Team



Board of Directors

Michael Nagel Chairperson	Pietro Bersani CPA, CGMA Director	Americo Cicchetti Independent Director	Frank Tirelli Independent Director	Ka Reg I Indep Dire
COMARIS DECOMENCIAR SOLUTIONS FRANKLIN GROUP	λλλ	MORE DOCOLImage: Docol	CILIAND	

Summary Balance Sheet & Cap Table

Balance Sheet Data As of March 31, 2022)	As Reported	As Adjusted ¹	Pre-Offering Cap Tab
Cash and cash equivalents	\$15,123,100	\$37,638,628	Common Stock
Working capital	\$12,625,800		Restricted Stock Units (\$10.37 Weighted average grant date fair value)
			Options (\$8.49 Weighted average exercise price)
Total assets	\$25,889,800		Warrants (\$7.43 Weighted average exercise price)
Total stockholders' equity	\$20,032,100	\$42,547,628	Fully Diluted Common Shares

1. Gives effect to the sale and issuance by us of 62,500,000 shares of common stock in this offering at an assumed combined offering price of \$0.40 per share of common stock and accompanying assuming no sale of Pre-Funded Warrants and no exercise of the Common Stock Warrants and after deducting estimated underwriting discounts and commissions and estimated offering expe

Value Proposition Summary



